Biotech News

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Pharmaceuticals (BCRX)BioCryst Pharmaceuticals2026-06-25 13:46 ESTEarnings

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026

Open original release

Related news

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst to Present at Upcoming Investor Conference

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst to Report First Quarter 2026 Financial Results on May 6

BCRXBioCryst Pharmaceuticals2026-06-25 13:46 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

BCRXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

BCRXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

BCRXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

BCRXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

BCRXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 9.91 USD
Market cap: 2.66B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States